However, the clinical value of the MLH1 promoter methylation analysis is much higher for the identification of MLH1 mutation carriers among patients with CRC [241,242] and is also applicable to endometrial cancers and probably to other tumor types. The gene discussed is MLH1; the disease is endometrial cancer.